The Renin-Angiotensin-Aldosterone System
A patient loses 1.5 liters of blood in an accident. Yet their arterial pressure barely falls. Within minutes, a hormonal cascade has already begun. It clamps down blood vessels and tells the kidneys to hoard every milliequivalent of sodium they can find. This is the renin-angiotensin-aldosterone system, or RAAS. It is one of the body's most powerful long-term blood pressure and blood volume controllers. RAAS matters because blood pressure regulation operates on two very different timescales. The baroreceptor reflex corrects pressure within seconds. But it fades over days as receptors reset. RAAS, by contrast, is the slow, durable system. It defends extracellular fluid volume and arterial pressure over hours to weeks. It does this by controlling how much salt and water the kidneys retain. Where sodium goes, water follows osmotically. So a hormone system built to conserve sodium is, at its core, a volume-conserving system. The big picture is a beautifully layered cascade. A kidney enzyme (renin) triggers production of a peptide hormone (angiotensin II). This hormone acts everywhere from arterioles to the adrenal cortex to the brain. It ultimately provokes release of a steroid hormone (aldosterone) that fine-tunes renal sodium reabsorption. Counterbalancing this whole system is a single stretch-sensitive signal from the heart itself — atrial natriuretic peptide (ANP). It pushes in the opposite direction whenever blood volume is too high. This article works through the molecular cascade step by step. It covers the classic experiments that revealed each link, and worked quantitative examples in hemorrhage and heart failure. It also examines the clinical drugs that exploit every node of this pathway. Together these connect renal physiology to cardiovascular medicine and, eventually, to how animals in different habitats manage salt and water at all.
- RAAS is a hormonal cascade triggered by low renal perfusion, low NaCl delivery, or sympathetic activation, and its endpoint is increased Na⁺ (and water) retention plus vasoconstriction.
- Renin (from juxtaglomerular cells) cleaves angiotensinogen to angiotensin I; ACE (mainly in lung capillaries) converts this to angiotensin II, the system's primary effector.
- Angiotensin II raises blood pressure directly (vasoconstriction), and indirectly via aldosterone (renal Na⁺ retention), ADH release, thirst, and sympathetic facilitation.
- Aldosterone acts on principal cells of the renal collecting duct, upregulating ENaC and Na⁺/K⁺-ATPase to reabsorb Na⁺ and secrete K⁺.
- Atrial natriuretic peptide, released by stretched atria, opposes RAAS at nearly every step, promoting natriuresis and vasodilation.
- The system is the direct pharmacological target of ACE inhibitors, ARBs, and aldosterone antagonists — among the most widely prescribed drugs in medicine.
RAAS is a negative-feedback cascade that senses falling blood pressure/volume at the kidney and restores it by retaining sodium (and thus water) and constricting vessels, with ANP providing the physiological counterweight.
The core idea
The renin-angiotensin-aldosterone system is a hormonal cascade that links renal blood flow sensing to systemic blood pressure and extracellular fluid volume control. Unlike fast neural reflexes, RAAS operates on a timescale of minutes to days, and its central logic is indirect: the kidney does not sense "blood pressure" as a single number but infers it from three local proxies — afferent arteriolar wall tension, NaCl concentration at the macula densa, and sympathetic nerve input — and responds by adjusting how much of the filtered sodium load it returns to the blood. The cascade's name traces its own logic. Renin is a proteolytic enzyme, not itself a hormone, secreted by granular cells of the juxtaglomerular apparatus. It cleaves circulating angiotensinogen (made constitutively by the liver) into the decapeptide angiotensin I, which is biologically nearly inert. Angiotensin-converting enzyme (ACE), concentrated on the luminal surface of pulmonary capillary endothelium, removes two C-terminal residues to produce the octapeptide angiotensin II, the system's true effector molecule. Angiotensin II then acts on multiple targets — vascular smooth muscle, the adrenal cortex, the hypothalamus, the proximal tubule, and sympathetic terminals — coordinating a multi-organ response aimed at one outcome: restoring effective circulating volume and arterial pressure.
Aldosterone, a mineralocorticoid steroid released from the adrenal cortex's zona glomerulosa, is the downstream hormone that does the fine, sustained work of sodium conservation at the distal nephron. It is worth distinguishing aldosterone's slow, genomic action (hours) from angiotensin II's fast, largely non-genomic vasoconstrictor action (seconds). The system is opposed by atrial natriuretic peptide (ANP), released from cardiac atrial myocytes when stretched by volume overload; ANP suppresses renin, opposes aldosterone, dilates vessels, and increases GFR and natriuresis. Together RAAS and ANP form a push-pull system analogous in logic to insulin and glucagon, but for salt and volume rather than glucose.
Mechanism
Step 1 — Triggers for renin release. Renin secretion from juxtaglomerular (JG) granular cells, located in the afferent arteriolar wall, is stimulated by three converging inputs: 1. Decreased afferent arteriolar pressure — sensed directly by the JG cells acting as intrinsic baroreceptors (a stretch-relaxation mechanism: less stretch → more renin). 2. Decreased NaCl delivery to the macula densa — a specialized patch of thick ascending limb cells adjacent to the JG apparatus that senses luminal Cl⁻ via the Na⁺-K⁺-2Cl⁻ cotransporter; falling NaCl flux triggers paracrine signals (including prostaglandins and reduced ATP/adenosine signaling) that stimulate renin release. 3. Increased renal sympathetic nerve activity — acting on β1-adrenergic receptors on JG cells, directly stimulating renin exocytosis. This is the pathway by which baroreceptor-driven sympathetic surges (e.g., during hemorrhage) recruit RAAS.
Step 2 — The enzymatic cascade. Renin, once released into the blood, has only one known substrate: angiotensinogen, an α2-globulin secreted continuously by hepatocytes at roughly constant plasma concentration. Renin cleaves the Leu-Val bond near the N-terminus, liberating angiotensin I (a decapeptide). Angiotensin I is hydrolyzed by ACE — a zinc metallopeptidase anchored on endothelial cell membranes, overwhelmingly concentrated in the pulmonary vasculature because of its enormous capillary surface area — removing the C-terminal His-Leu dipeptide to yield angiotensin II. This step happens with a single circulatory pass through the lungs, so angiotensin II appears in arterial blood almost as fast as angiotensin I is made. ACE has a second, unrelated job: it degrades bradykinin, a vasodilator peptide — a fact that explains a major class of drug side effects (see below).
Step 3 — Angiotensin II, the multi-target effector. Angiotensin II acts through G-protein-coupled AT1 receptors (Gq-coupled, IP3/Ca²⁺ signaling) on:
| Target | Effect |
|---|---|
| Vascular smooth muscle (systemic arterioles) | Direct vasoconstriction → ↑ total peripheral resistance |
| Zona glomerulosa of adrenal cortex | ↑ Aldosterone synthesis and secretion |
| Proximal tubule epithelium | ↑ Na⁺/H⁺ exchanger (NHE3) activity → ↑ Na⁺ and HCO₃⁻ reabsorption |
| Hypothalamus (subfornical organ, circumventricular) | ↑ Thirst; ↑ ADH (vasopressin) release from posterior pituitary |
| Sympathetic nerve terminals | Facilitates norepinephrine release, amplifying vasoconstriction |
| Efferent arteriole (mild constriction) | Helps maintain GFR when renal perfusion pressure falls |
Notice the redundancy: angiotensin II raises blood pressure and volume through at least five parallel mechanisms simultaneously — a hallmark of physiological systems where failure would be catastrophic.
Step 4 — Aldosterone's cellular action. Aldosterone is a steroid hormone: it diffuses into principal cells of the cortical collecting duct (and connecting tubule) and binds cytoplasmic mineralocorticoid receptors. The hormone-receptor complex translocates to the nucleus and acts as a transcription factor, inducing:
- Increased synthesis and apical membrane insertion of epithelial sodium channels (ENaC)
- Increased synthesis and basolateral insertion of Na⁺/K⁺-ATPase pumps
- Increased mitochondrial ATP production to power the pumps
- Increased apical ROMK potassium channels, enabling K⁺ secretion
The net cellular effect: Na⁺ enters principal cells passively through ENaC down its electrochemical gradient, then is actively pumped into the interstitium by Na⁺/K⁺-ATPase, creating a lumen-negative potential that drives K⁺ secretion into urine and enhances H⁺ secretion by adjacent intercalated cells. This is why aldosterone excess causes hypokalemia and metabolic alkalosis alongside sodium retention — a clinically important triad. Because the collecting duct handles only the last ~2-3% of filtered sodium, aldosterone is a fine-tuning hormone, not a bulk regulator — but over days, sustained changes in its secretion rate can shift total body Na⁺ by tens of grams, enough to change plasma volume by liters.
Step 5 — ANP as the counter-regulator. When atrial wall stretch increases (elevated venous return/blood volume), atrial myocytes release ANP (and the related B-type natriuretic peptide, BNP, from ventricles). ANP:
- Directly relaxes vascular smooth muscle (vasodilation) via cGMP signaling
- Increases GFR by dilating afferent and constricting efferent arterioles
- Directly inhibits Na⁺ reabsorption in the collecting duct (blocks ENaC)
- Suppresses renin release from JG cells
- Suppresses aldosterone secretion directly at the adrenal cortex
- Inhibits ADH release
The result is natriuresis and diuresis — ANP is, in effect, physiology's own diuretic and mild antihypertensive, released exactly when RAAS should be switched off.
The evidence
Tigerstedt and Bergman (1898): the discovery of renin. Swedish physiologist Robert Tigerstedt and his student Per Bergman injected saline extracts of rabbit renal cortex into other rabbits and observed a sustained rise in blood pressure. They named the pressor substance "renin." This finding sat largely unexplored for nearly forty years because the mechanism was unclear and the effect was hard to reproduce reliably with the crude extracts available.
Goldblatt (1934): renal ischemia causes hypertension. Harry Goldblatt placed a silver clamp on one renal artery of a dog (the "Goldblatt clamp"), reducing renal perfusion pressure without causing infarction. Blood pressure rose and remained elevated — the first controlled demonstration that reduced renal blood flow alone, not renal damage broadly, is sufficient to produce sustained hypertension. This "one-kidney, one-clip" and later "two-kidney, one-clip" models became the standard tools for dissecting renin's role, and directly implicated the kidney (not the heart or brain) as the pressure-sensing origin of a circulating pressor factor.
Braun-Menéndez and Page (independently, 1940): identification of angiotensin. Working independently in Argentina and the United States, Eduardo Braun-Menéndez's group and Irvine Page's group each showed that renin itself was not the final pressor agent. Rather, renin acted enzymatically on a plasma protein substrate to generate a separate, much more potent pressor peptide. The Argentine group called it "hypertensin," Page's group called it "angiotonin" — the names were later merged into "angiotensin" by international agreement in 1958. This resolved a genuine controversy: was the pressure rise due to renin directly, or to a downstream product? Cross-mixing experiments (renin from one species plus substrate plasma from another) showed the reaction was substrate-limited and enzymatic, proving the cascade model rather than a single-hormone model.
Skeggs et al. (1956): purification of angiotensin I and II and discovery of the converting enzyme. Leonard Skeggs and colleagues purified and sequenced the decapeptide (angiotensin I) and showed it required a separate enzymatic step to become the fully active octapeptide (angiotensin II), identifying "converting enzyme" activity in plasma and later shown to be concentrated in lung tissue. This established the full three-tier cascade (renin → angiotensin I → angiotensin II) rather than a two-step model, and explained why intravenously infused angiotensin I is far less potent unless it first passes through the pulmonary circulation.
Laragh and colleagues (1960s): aldosterone as the RAAS effector on sodium balance. John Laragh's clinical studies linked plasma renin activity to aldosterone secretion rates across a spectrum of sodium intake and hypertensive states, demonstrating in humans that renin, not ACTH, is the dominant physiological regulator of aldosterone (except during severe stress). This clinical renin-aldosterone profiling became a diagnostic tool still used today to distinguish primary aldosteronism (low renin, high aldosterone) from renovascular hypertension (high renin, high aldosterone).
De Bold et al. (1981): discovery of atrial natriuretic peptide. Adolfo de Bold and colleagues injected crude extracts of rat atrial tissue (rich in electron-dense granules previously of unknown function) into rats and observed a rapid, dramatic natriuresis and diuresis — far greater than that produced by equivalent extracts of ventricular tissue. This proved that the atria themselves are an endocrine organ secreting a natriuretic hormone in response to stretch, providing the physiological antagonist to RAAS and completing the volume-control circuit as understood today.
Worked examples
Example 1 — Hemorrhage and the RAAS response, quantified. A trauma patient loses 1200 mL of blood (about 24% of a 5000 mL blood volume). Mean arterial pressure falls from 95 mmHg to 78 mmHg. Track the cascade: 1. Baroreceptor unloading → ↑ sympathetic outflow → renal afferent arteriolar constriction → renal blood flow falls disproportionately (renal autoregulation is overridden at this degree of hypotension). 2. Reduced afferent pressure and reduced NaCl delivery to the macula densa (GFR has fallen) both stimulate JG cells; sympathetic β1 stimulation adds a third, direct drive. Plasma renin activity can rise 5- to 10-fold within 10-15 minutes. 3. Angiotensin II rises correspondingly; because ACE is not rate-limiting, angiotensin II tracks angiotensin I production closely. 4. Angiotensin II directly vasoconstricts remaining perfused vascular beds (splanchnic, renal, cutaneous) — helping raise MAP back toward 85-90 mmHg within 30-60 minutes purely from this mechanism, before any fluid is regained. 5. Aldosterone secretion increases over 1-2 hours, cutting urinary Na⁺ excretion from a baseline of roughly 150 mEq/day toward under 10 mEq/day — nearly complete renal sodium conservation. 6. ADH release (aldosterone's "sister" response, also angiotensin II-driven) adds free water retention, so plasma osmolality is defended even as volume is restored. Net quantitative logic: a 24% blood volume loss is compensated first by a redistribution (venoconstriction returning ~10-15% of blood volume to circulation from capacitance vessels), second by RAAS-driven vasoconstriction and Na⁺/water retention over hours, and only over days is red cell mass restored via erythropoietin. RAAS is thus the volume-restoring, not the immediate pressure-restoring, layer.
Example 2 — Distinguishing two causes of secondary hypertension using renin/aldosterone ratios. A clinician sees two hypertensive patients, both with plasma aldosterone concentration (PAC) of 24 ng/dL (elevated; normal roughly 4-10 ng/dL upright).
- Patient A: plasma renin activity (PRA) = 6.5 ng/mL/h (elevated; normal ~1-2.5 upright).
PAC/PRA ratio = 24/6.5 ≈ 3.7.
- Patient B: PRA = 0.2 ng/mL/h (suppressed).
PAC/PRA ratio = 24/0.2 = 120. Interpretation: Patient A has high aldosterone driven by high renin — consistent with renovascular hypertension (e.g., renal artery stenosis, a modern Goldblatt-clamp scenario), where reduced renal perfusion appropriately triggers the whole cascade. Patient B has high aldosterone despite suppressed renin — the adrenal gland is autonomously overproducing aldosterone (primary aldosteronism, e.g., an adrenal adenoma), and the resulting volume expansion has appropriately shut off renin via negative feedback (the elevated blood pressure and volume are sensed normally by the kidney, which correctly stops secreting renin — the defect is upstream, at the adrenal). A PAC/PRA ratio above roughly 20-30 (with an elevated absolute PAC) is the standard screening threshold for primary aldosteronism. This single ratio, built directly from the cascade logic above, is a genuine bedside application of RAAS physiology.
Common misconceptions & traps
| Misconception | Correction |
|---|---|
| "Renin is the hormone that raises blood pressure." | Renin is an enzyme; angiotensin II is the primary pressor hormone. Renin's only substrate is angiotensinogen. |
| "Aldosterone and ADH do the same thing." | Aldosterone drives active Na⁺ reabsorption (and K⁺ secretion); ADH drives passive water reabsorption via aquaporins. They are complementary, not redundant. |
| "ACE inhibitors only lower blood pressure by blocking angiotensin II." | ACE also degrades bradykinin; inhibiting ACE raises bradykinin, contributing to the characteristic dry cough and to some of the vasodilatory benefit. |
| "More aldosterone always means more total renin activity." | Not in primary aldosteronism, where autonomous adrenal secretion suppresses renin via negative feedback — high aldosterone with low renin. |
| "The collecting duct is where most filtered Na⁺ is reabsorbed, so aldosterone controls most of Na⁺ balance." | The proximal tubule reabsorbs ~65% and the loop ~25% of filtered Na⁺, independent of aldosterone; the aldosterone-sensitive segment fine-tunes only the last few percent — but this last few percent is enough to match intake to excretion precisely. |
| "RAAS only responds to blood pressure." | It responds to three distinct inputs — arteriolar pressure, macula densa NaCl delivery, and sympathetic tone — which can be dissociated (e.g., low-salt diet activates RAAS without hypotension). |
The scientist behind it
Origins · 1 minRobert Tigerstedt and how this was discovered
Robert Tigerstedt was a Finnish-Swedish physiologist working at the Karolinska Institute at a time when endocrinology as a field barely existed — hormones would not even be given that name until 1905. Trained broadly across cardiovascular and comparative physiology, Tigerstedt was interested in whether the kidney, beyond filtering urine, might also communicate chemically with the circulation. Working with his medical student Per Bergman, he prepared saline extracts of rabbit renal cortex and injected them intravenously into other rabbits, observing a clear and repeatable rise in blood pressure. They published this in 1898 and coined the name "renin" for the active principle — remarkably prescient given that the actual mechanism (an enzyme acting on a separate plasma substrate to generate a distinct pressor peptide) would not be worked out for another forty years. Tigerstedt's finding was largely dismissed or ignored by contemporaries, partly because other groups failed to reproduce the pressor effect reliably with cruder or degraded extracts, and it took Harry Goldblatt's 1934 clamp experiments to reignite interest in a renal pressor substance and set off the chain of discoveries — Page, Braun-Menéndez, Skeggs — that built the modern RAAS cascade on Tigerstedt's original, correctly-named but long-unappreciated discovery.
Where this matters today
RAAS is arguably the single most pharmacologically exploited hormone system in medicine.
- ACE inhibitors (e.g., lisinopril, enalapril) block the conversion of angiotensin I to
angiotensin II, lowering blood pressure and reducing aldosterone; their bradykinin-related cough is a direct mechanistic consequence of ACE's dual substrate specificity.
- Angiotensin receptor blockers (ARBs) (e.g., losartan) block AT1 receptors directly,
achieving similar hemodynamic effects without affecting bradykinin, avoiding the cough.
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) block aldosterone's
action at the principal cell, used in resistant hypertension, heart failure, and primary aldosteronism; they cause hyperkalemia as a predictable mechanistic side effect.
- Direct renin inhibitors (aliskiren) block the first, rate-limiting enzymatic step.
- Heart failure management exploits BNP/ANP biology directly: recombinant BNP (nesiritide)
and neprilysin inhibitors (which block natriuretic peptide breakdown, used in combination drugs like sacubitril/valsartan) amplify the natural counter-regulatory arm of this system.
- Diagnosis of secondary hypertension relies on the PRA/aldosterone ratio logic demonstrated
above, distinguishing renovascular disease from primary adrenal disease.
- Chronic kidney disease and diabetic nephropathy management uses ACE inhibitors/ARBs to
reduce intraglomerular pressure (via efferent arteriolar dilation), slowing progression of proteinuric kidney disease — a direct clinical application of angiotensin II's efferent arteriolar constrictor role in Regulation of GFR and Renal Blood Flow.
- Veterinary and comparative physiology studies RAAS activity across species with radically
different salt/water challenges — a preview of how Comparative Osmoregulation Across Environments varies this same core cascade for marine, freshwater, and desert life, building on the sodium-handling logic introduced in Sodium and Water Balance.
Ask the tutor: How does chronic RAAS overactivation in heart failure eventually become maladaptive, and why do ACE inhibitors improve survival despite initially lowering blood pressure that the failing heart seems to need?
Why does aldosterone cause both sodium retention and potassium loss?
Aldosterone upregulates ENaC channels and Na⁺/K⁺-ATPase pumps in collecting duct principal cells. Na⁺ enters the cell through ENaC and is pumped into blood by Na⁺/K⁺-ATPase, which simultaneously pumps K⁺ into the cell. This buildup of intracellular K⁺, combined with the lumen-negative electrical gradient created by Na⁺ reabsorption, drives K⁺ out through apical ROMK channels into the tubular fluid. The two effects are mechanistically coupled through the same pump and the same electrical gradient, which is why aldosterone excess (as in primary aldosteronism) classically produces both hypertension from Na⁺/volume retention and hypokalemia from enhanced K⁺ secretion, often with metabolic alkalosis from parallel H⁺ secretion.
Why does angiotensin II act on the efferent arteriole differently from other vessels?
Angiotensin II vasoconstricts arterioles throughout the body to raise systemic pressure, but at the glomerulus the efferent arteriole is comparatively more sensitive to angiotensin II than the afferent arteriole at physiological concentrations. Constricting the efferent arteriole raises glomerular capillary hydrostatic pressure, helping preserve GFR even as renal blood flow falls during hypotension — an adaptive mechanism. This is also why ACE inhibitors/ARBs, by removing this efferent constriction, lower intraglomerular pressure; that's beneficial in diabetic nephropathy (reduces damaging hyperfiltration) but can transiently drop GFR and raise creatinine when renal perfusion is already compromised, such as in bilateral renal artery stenosis.
How fast does each part of the RAAS cascade actually work?
Renin release in response to sympathetic stimulation or reduced macula densa NaCl can begin within seconds to a minute. Angiotensin I formation and its near-immediate pulmonary conversion to angiotensin II follow within one circulatory pass (seconds). Angiotensin II's direct vasoconstrictor effect is essentially immediate. Aldosterone, being a steroid requiring gene transcription and new protein synthesis in target cells, has an onset of roughly 30-60 minutes and a peak effect over hours, with maximal renal sodium-conserving effect not fully realized for a day or more. This is why the vasoconstrictor arm of RAAS matters acutely (e.g., in hemorrhage) while the aldosterone arm matters for sustained, day-to-day sodium balance.
Does RAAS respond to dietary salt intake as well as blood volume?
Yes. A chronic low-salt diet reduces extracellular fluid volume slightly, lowering renal perfusion pressure and NaCl delivery to the macula densa, both of which chronically elevate plasma renin activity and aldosterone. A high-salt diet does the opposite, suppressing RAAS. This is the physiological basis for renin/aldosterone testing protocols in endocrinology, which standardize dietary sodium intake before measuring these hormones — otherwise a low-renin result could simply reflect a high-salt diet rather than adrenal pathology. It's also why antihypertensive treatment guidelines pair ACE inhibitors/ARBs with dietary sodium restriction: the two interventions act on the same axis synergistically.
Why do ACE inhibitors cause a dry cough but ARBs don't?
ACE is not selective for the angiotensin pathway; it is identical to "kininase II," the primary enzyme that degrades bradykinin, a potent vasodilator and pro-inflammatory peptide. Inhibiting ACE therefore raises bradykinin levels, which sensitizes airway sensory nerve fibers and provokes a chronic dry cough in roughly 5-20% of patients, along with contributing partly to ACE inhibitors' antihypertensive benefit through vasodilation. Angiotensin receptor blockers act downstream, at the AT1 receptor itself, leaving bradykinin metabolism untouched — they achieve similar blockade of angiotensin II's effects without the cough, though rare angioedema can still occur via receptor-independent mechanisms.
How does the body distinguish "true" volume depletion from just low sodium intake for RAAS purposes?
It largely doesn't distinguish the causes directly — RAAS responds to the physiological consequence (reduced effective circulating volume and/or reduced NaCl delivery), regardless of whether the cause is hemorrhage, dehydration, low dietary sodium, heart failure with reduced cardiac output, or cirrhosis with third-spacing. This is a feature, not a limitation: the JG apparatus's three sensors (arteriolar pressure, macula densa NaCl, sympathetic tone) are reading proxies for "is effective circulating volume adequate," and the appropriate response — conserve sodium and water, vasoconstrict — is the same corrective action regardless of cause. This is also why RAAS becomes pathologically overactive in heart failure and cirrhosis: the kidney correctly senses reduced effective perfusion even though total body volume and total body sodium may already be markedly elevated, driving further fluid retention and edema.
How is RAAS different from the ADH/thirst system, and how are they linked?
ADH (vasopressin) and thirst are primarily regulated by plasma osmolality, sensed by hypothalamic osmoreceptors, and they control free water balance independent of sodium content. RAAS is primarily regulated by effective circulating volume and controls sodium balance (which secondarily drags water with it osmotically). The two systems are linked because angiotensin II directly stimulates both ADH release and thirst at the hypothalamus, meaning a strong RAAS activation (e.g., during hemorrhage) recruits the osmotic system too, even without a large change in plasma osmolality — a cross-talk that ensures severe volume depletion triggers water intake and retention as well as sodium conservation, prioritizing survival over precise osmoregulation in the short term.